
Opinion|Videos|April 18, 2025
Population Outcomes and Return on Value With CGMs
Experts discuss the metrics used to evaluate continuous glucose monitoring (CGM)'s comprehensive return on investment, including both cost savings and quality measure performance, and identify which patient populations demonstrate the strongest combined benefits in costs, quality measures, and outcomes, along with how these groups are prioritized for CGM access.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What metrics do you use to evaluate CGM's comprehensive return on investment, including both cost savings and quality measure performance?
- Which patient populations demonstrate the strongest combined benefits in costs, quality measures, and outcomes, and how do you prioritize these groups for CGM access?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Most Favored Nation Drug Pricing Moves Forward, but Experts Warn Details Are Still Missing
2
Medicaid Work Requirements Set to Leave Millions Without Insurance
3
Timely Outpatient Follow-Up Reduces Hospital Readmissions
4
Oncology Landscape Continues to Evolve With Expanded Indications, First-in-Class Therapies
5
















































